Q1 2022 Reporting

Highlights SER150 clinical study in Australia is still delayed after Covid19 lockdownsSerodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.The Group qualified for and received a “Patent…

Continue ReadingQ1 2022 Reporting